LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "neoantigen" as a keyword



A Potent Micron Neoantigen Tumor Vaccine GP‐Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models

Sign Up to like & get
recommendations! Published in 2022 at "Advanced Science"

DOI: 10.1002/advs.202201496

Abstract: Therapeutic tumor neoantigen vaccines have been widely studied given their good safety profile and ability to avoid central thymic tolerance. However, targeting antigen‐presenting cells (APCs) and inducing robust neoantigen‐specific cellular immunity remain challenges. Here, a… read more here.

Keywords: system; antitumor; tumor; neoantigen ... See more keywords

Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Extracellular Vesicles"

DOI: 10.1002/jev2.12289

Abstract: Abstract Neoantigens derived from mutant proteins in tumour cells could elicit potent personalized anti‐tumour immunity. Nevertheless, the layout of vaccine vehicle and synthesis of neoantigen are pivotal for stimulating robust response. The power of synthetic… read more here.

Keywords: bacteria derived; neoantigen; bdvs neo; immunity ... See more keywords

Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth

Sign Up to like & get
recommendations! Published in 2020 at "Translational Oncology"

DOI: 10.1016/j.tranon.2020.100856

Abstract: The immunogenic clonal-fraction threshold in heterogeneous solid-tumor required to induce effective bystander-killing of non-immunogenic subclones is unknown. Pancreatic cancer poses crucial challenges for immune therapeutic interventions due to low mutational-burden and consequent lack of neoantigens.… read more here.

Keywords: neoantigen; pancreatic cancer; cancer; growth ... See more keywords

Nanovaccine Based on a Biepitope Antigen to Potentiate the Immunogenicity of a Neoantigen.

Sign Up to like & get
recommendations! Published in 2023 at "ACS macro letters"

DOI: 10.1021/acsmacrolett.2c00742

Abstract: Specific neoantigens are promising candidates for personalized cancer vaccines and immunotherapies, whereas the low immunogenicity and physicochemical variability are the main challenges in clinical trials. Herein, based on the rational design of neoantigens, we developed… read more here.

Keywords: biepitope; neoantigen; immunogenicity; biepitope nanovaccines ... See more keywords

Reprogramming Immunosuppressive Niches and the Cancer Immunity Cycle in Pancreatic Cancer with Neoantigen mRNA Plus Immune Adjuvant Nanocarrier Strategies.

Sign Up to like & get
recommendations! Published in 2025 at "ACS nano"

DOI: 10.1021/acsnano.5c14753

Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies, driven by an immune-excluded, desmoplastic tumor microenvironment (TME), a low neoantigen burden, and resistance to immune checkpoint blockade. Recent progress in immunotherapy has emerged from… read more here.

Keywords: cancer; immunity; neoantigen; reprogramming immunosuppressive ... See more keywords

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Sign Up to like & get
recommendations! Published in 2017 at "Nature"

DOI: 10.1038/nature24462

Abstract: Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens… read more here.

Keywords: neoantigen; long term; survivors pancreatic; term survivors ... See more keywords

Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus

Sign Up to like & get
recommendations! Published in 2025 at "EMBO Molecular Medicine"

DOI: 10.1038/s44321-025-00225-3

Abstract: Neoantigen vaccine is a promising breakthrough in tumor immunotherapy. However, the application of this highly personalized strategy in the treatment of solid tumors is hindered by several obstacles, including very costly and time-consuming preparation steps,… read more here.

Keywords: vaccine primed; neoantigen; tumor; peptide mhc ... See more keywords

Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy

Sign Up to like & get
recommendations! Published in 2023 at "Expert Opinion on Drug Delivery"

DOI: 10.1080/17425247.2023.2168640

Abstract: ABSTRACT Introduction Cancer vaccine represents a promising strategy toward personalized immunotherapy, and its therapeutic potency highly relies on the specificity of tumor antigens. Among these extensively studied tumor antigens, neoantigens, a type of short synthetic… read more here.

Keywords: immunotherapy; neoantigen; tumor; biomaterials assisted ... See more keywords

The mutant neoantigen specific T cell is a personalized immunotherapy in refractory solid tumour

Sign Up to like & get
recommendations! Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz253.054

Abstract: Abstract Background Immune checkpoint inhibitors are an important therapy. However, their essence is nonspecific and efficiency of single usage is not satisfactory. The mutant neoantigen specific T (Nas-T) cell, as an adoptive cell treatment, is… read more here.

Keywords: neoantigen; neoantigen specific; cell personalized; personalized immunotherapy ... See more keywords

The role of tumour neoantigens in the differential response to immunotherapy (IO) in EGFR and BRAF mutated lung cancers: Quantity or quality?

Sign Up to like & get
recommendations! Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz253.084

Abstract: Abstract Background Lung cancer patients with activating EGFR mutations tend to respond poorly to IO, but this is not true for all activating mutation driven lung cancers. Recent data show that patients with BRAF mutations… read more here.

Keywords: neoantigen; egfr; braf; advisory consultancy ... See more keywords

Combination Immune Treatment of a Highly Aggressive Orthotopic Murine Glioblastoma With Checkpoint Blockade Inhibition and Neoantigen Vaccination

Sign Up to like & get
recommendations! Published in 2019 at "Neurosurgery"

DOI: 10.1093/neuros/nyz310_153

Abstract: The treatment of glioblastoma remains a challenge for modern therapy. Checkpoint blockade inhibitors (CBI), designed to block inhibitory T-cell signaling, represent attractive potential therapeutic interventions. However, glioblastoma response rates to CBI remain low. To this… read more here.

Keywords: glioblastoma; neoantigen; treatment; combination ... See more keywords